Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

199.08USD
23 Aug 2019
Change (% chg)

$-4.34 (-2.13%)
Prev Close
$203.42
Open
$203.09
Day's High
$203.51
Day's Low
$198.05
Volume
1,485,330
Avg. Vol
1,203,724
52-wk High
$211.89
52-wk Low
$166.30

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.17
Market Cap(Mil.): $107,397.50
Shares Outstanding(Mil.): 609.94
Dividend: 1.45
Yield (%): 3.29

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 14.05 29.73 33.85
EPS (TTM): 12.53 -- --
ROI: 14.42 13.04 12.69
ROE: 61.05 14.12 17.13

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

10 Aug 2019

UPDATE 3-Amgen results beat estimates, lung cancer trial planned

July 30 Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.

31 Jul 2019

Amgen quarterly revenue dips 3% but profit tops Street expectations

July 30 Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.

31 Jul 2019

UPDATE 3-Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

July 30 Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection.

30 Jul 2019

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

16 Jul 2019

Gilead invests $5 billion to deepen ties with biotech Galapagos

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares more than 18% to an all-time high on Monday.

16 Jul 2019

UPDATE 4-Gilead invests $5 bln to deepen ties with biotech Galapagos

* Gilead makes $3.95 bln upfront payment, $1.1 equity investment

16 Jul 2019

Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

New York The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators. | Video

04 Jun 2019

Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

New York The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators.

04 Jun 2019

US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

* Facebook, Amazon, Alphabet tumble on fears of regulatory risks

04 Jun 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates